Encision Completes $500,000 Private Placement
Encision (OTC PINK:ECIA), a medical device company specializing in Active Electrode Monitoring (AEM庐) Technology, has completed a $500,000 private placement of common stock. The company issued 5 million common shares at $0.10 per share to a group of investors including directors, executive officers, existing shareholders, and new investors.
The funding will support ongoing operations and the development of their new ENT Device, expected to launch in early 2026. Following the private placement, Encision's total outstanding common shares increased to 16,879,645. The issued shares are restricted and do not have registration rights.
Encision (OTC PINK:ECIA), azienda di dispositivi medici specializzata nella tecnologia Active Electrode Monitoring (AEM庐), ha chiuso un placement privato di 500.000$ mediante emissione di azioni ordinarie. Sono state emesse 5 milioni di azioni ordinarie a 0,10$ ciascuna a un gruppo di investitori che include amministratori, dirigenti, soci esistenti e nuovi sottoscrittori.
I fondi serviranno a sostenere le attivit脿 correnti e lo sviluppo di un nuovo dispositivo ORL, la cui commercializzazione 猫 prevista per l'inizio del 2026. Dopo l'operazione il numero totale di azioni ordinarie in circolazione 猫 salito a 16.879.645. Le azioni emesse sono soggette a restrizioni e non godono di diritti di registrazione.
Encision (OTC PINK:ECIA), empresa de dispositivos m茅dicos especializada en la tecnolog铆a Active Electrode Monitoring (AEM庐), ha completado una colocaci贸n privada de 500.000$ de acciones ordinarias. Se emitieron 5 millones de acciones ordinarias a 0,10$ por acci贸n a un grupo de inversores que incluye directores, altos ejecutivos, accionistas existentes y nuevos inversores.
Los fondos apoyar谩n las operaciones en curso y el desarrollo de su nuevo dispositivo ORL, previsto para lanzarse a principios de 2026. Tras la colocaci贸n privada, el total de acciones ordinarias en circulaci贸n aument贸 a 16.879.645. Las acciones emitidas est谩n restringidas y no tienen derechos de registro.
Encision (OTC PINK:ECIA)電� Active Electrode Monitoring(AEM庐) 旮办垹鞚� 鞝勲鞙茧 頃橂姅 鞚橂旮瓣赴 須岇偓搿�, 50毵� 雼煬 攴滊鞚� 靷欤检嫕 氚滍枆鞚� 鞕勲頄堨姷雼堧嫟. 須岇偓電� 鞚挫偓, 鞛勳洂, 旮办〈 欤检＜ 氚� 鞁犼窚 韴瀽鞛愲ゼ 韽暔頃� 韴瀽鞛� 攴鸽９鞐� 欤茧嫻 0.10雼煬鞐� 500毵� 氤错喌欤�毳� 氚滍枆頄堨姷雼堧嫟.
鞚措矆 鞛愱笀鞚� 順勳灛 鞖挫榿瓿� 鞁犿槙 鞚措箘鞚疙泟瓿�(ENT) 鞛レ箻 臧滊皽鞚� 歆�鞗愴晿電� 雿� 靷毄霅橂┌, 頃措嫻 鞛レ箻電� 2026雲� 齑� 於滌嫓霅� 鞓堨爼鞛呺媹雼�. 靷 氚滍枆 頉� Encision鞚� 齑� 氚滍枆 氤错喌欤茧姅 16,879,645欤�搿� 歃濌皜頄堨姷雼堧嫟. 氚滍枆霅� 欤检嫕鞚� 鞝滍暅鞚� 鞛堨溂氅� 霌彪 甓岆Μ臧� 鞐嗢姷雼堧嫟.
Encision (OTC PINK:ECIA), soci茅t茅 de dispositifs m茅dicaux sp茅cialis茅e dans la technologie Active Electrode Monitoring (AEM庐), a finalis茅 un placement priv茅 de 500 000 $ d'actions ordinaires. La soci茅t茅 a 茅mis 5 millions d'actions ordinaires 脿 0,10 $ l'action 脿 un groupe d'investisseurs comprenant des administrateurs, des dirigeants, des actionnaires existants et de nouveaux investisseurs.
Les fonds financeront les op茅rations courantes et le d茅veloppement de leur nouvel appareil ORL, dont le lancement est pr茅vu pour le d茅but 2026. Apr猫s le placement priv茅, le nombre total d'actions ordinaires en circulation est pass茅 脿 16 879 645. Les actions 茅mises sont restreintes et ne disposent pas de droits d'enregistrement.
Encision (OTC PINK:ECIA), ein Medizinger盲teunternehmen mit Schwerpunkt auf Active Electrode Monitoring (AEM庐)-Technologie, hat eine Privatplatzierung 眉ber 500.000$ von Stammaktien abgeschlossen. Es wurden 5 Millionen Stammaktien zu je 0,10$ an eine Investorengruppe ausgegeben, zu der Direktoren, F眉hrungskr盲fte, bestehende Aktion盲re und neue Investoren geh枚ren.
Die Mittel sollen den laufenden Gesch盲ftsbetrieb und die Entwicklung des neuen HNO-Ger盲ts unterst眉tzen, dessen Markteinf眉hrung f眉r Anfang 2026 geplant ist. Nach der Privatplatzierung stieg die Gesamtzahl der ausstehenden Stammaktien auf 16.879.645. Die ausgegebenen Aktien unterliegen Beschr盲nkungen und besitzen keine Registrierungsrechte.
- Secured $500,000 in necessary funding for operations and product development
- New ENT Device launch planned for early 2026
- Investment participation from company insiders shows management confidence
- Significant dilution with 5 million new shares issued at $0.10 per share
- Restricted shares with no registration rights may limit investor liquidity
- Company appears to require funding to continue operations, indicating cash flow concerns
BOULDER, CO / / August 22, 2025 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM庐) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced that on August 19, 2025 it completed a
"We are happy to have secured necessary funds to enable us to continue operations and prepare for the expected launch of our new ENT Device in early 2026" said Gregory Trudel, President and CEO of Encision. "We have great expectations for the success of the new device and are happy to have sufficient funds to complete development and ramp our sales efforts." Pursuant to the securities purchase agreement, the Company issued 5 million common shares at a per share price of
Encision Inc. designs and markets a portfolio of high-performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit .
In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2024 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.
CONTACT: Brandon Shepard , Encision Inc., 303-444-2600, [email protected]
SOURCE: Encision, Inc.
View the original on ACCESS Newswire
FAQ
What is the size and price of Encision's (ECIA) private placement in August 2025?
How will Encision (ECIA) use the proceeds from the private placement?
Who participated in Encision's (ECIA) private placement?
How many shares does Encision (ECIA) have outstanding after the private placement?
What are the restrictions on the shares issued in Encision's (ECIA) private placement?
